U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H24O2.C2H6NO3S.K
Molecular Weight 363.555
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM TAURINE LAURATE

SMILES

[K+].NCCS([O-])(=O)=O.CCCCCCCCCCCC(O)=O

InChI

InChIKey=YXUKIOYEWGMHBJ-UHFFFAOYSA-M
InChI=1S/C12H24O2.C2H7NO3S.K/c1-2-3-4-5-6-7-8-9-10-11-12(13)14;3-1-2-7(4,5)6;/h2-11H2,1H3,(H,13,14);1-3H2,(H,4,5,6);/q;;+1/p-1

HIDE SMILES / InChI

Molecular Formula C12H24O2
Molecular Weight 200.3178
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H6NO3S
Molecular Weight 124.139
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 | https://www.ncbi.nlm.nih.gov/pubmed/26208967

Taurine is a semi-essential amino acid and is not incorporated into proteins. Taurine is considered conditionally essential because it cannot be synthesized by infants younger than 4-6 weeks, and it may not be adequately synthesized in patients receiving long-term parenteral nutrition and patients with short-term hypermetabolic conditions. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg. Taurine is a component of energy drinks, with many contain 1000 mg per serving. In medicine, taurine supplementation demonstrated efficacy in relieving symptoms of heart failure, hepatitis, hypertension and psychotic disorder. Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear mechanisms. The cellular and biochemical mechanisms mediating the actions of taurine are not fully known.

Originator

Curator's Comment: Taurin was first isolated from ox bile in 1827.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
406.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TAURINE

Approved Use

Taking 2-3 grams of taurine by mouth one to two times daily for 6-8 weeks seems to improve heart function and symptoms in patients with moderate heart failure to severe heart failure. Some patients with severe heart failure rapidly improve from NYHA class IV to II after 4-8 weeks of treatment. Improvement seems to continue for as long as taurine treatment is continued, up to one year.
Palliative
TAURINE

Approved Use

Taking 1.5-4 grams of taurine daily for up to 3 months improves liver function in people with hepatitis.
Preventing
URSA Complex

Approved Use

Taurine is a component of energy drinks used for relieving of fatigue
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[A study on the mechanism of taurine postponing the aging process of human fetal brain neural cells].
1997 Mar
Sodium nitroprusside-induced seizure and taurine release from rat hippocampus.
2000
Calcium-mediated transductive systems and functionally active gap junctions in astrocyte-like GL15 cells.
2001
Two years' experience with Dialock and CLS (a new antimicrobial lock solution).
2001
Zinc and the eye.
2001 Apr
Conditioned nutritional deficiencies in the cardiomyopathic hamster heart.
2001 Apr
Transport of L-carnitine in isolated cerebral cortex neurons.
2001 Apr
Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits.
2001 Apr
Fertilizability and developmental capacity of bovine oocytes cultured individually in a chemically defined maturation medium.
2001 Apr 15
Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs investigated with a human recombinant enzyme.
2001 Apr 6
Mast cell numbers in the young rat thalamus: a search for control factors.
2001 Aug
The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease.
2001 Feb
Hamster sperm glycine receptor: evidence for its presence and involvement in the acrosome reaction.
2001 Feb
Influence of protein kinases on the osmosensitive release of taurine from cerebellar granule neurons.
2001 Feb
Can this pill stop you from hitting the bottle?
2001 Feb 12
[Effect of taurine on the microvessel exchange function and adrenergic response of veins and arteries in the cat skeletal muscle].
2001 Jan
MR diffusion imaging and 1H spectroscopy in a child with medulloblastoma. A case report.
2001 Jan
Studies on the effects of lactate transport inhibition, pyruvate, glucose and glutamine on amino acid, lactate and glucose release from the ischemic rat cerebral cortex.
2001 Jan
Nucleoside transport inhibition in ischemic myocardium results in enhanced taurine efflux.
2001 Jan 5
Taurine modulates catalase, aldehyde dehydrogenase, and ethanol elimination rates in rat brain.
2001 Jan-Feb
The effect of taurine depletion by beta-alanine treatment on the susceptibility to ethanol-induced hepatic dysfunction in rats.
2001 Jan-Feb
Dietary taurine manipulations in aged male Fischer 344 rat tissue: taurine concentration, taurine biosynthesis, and oxidative markers.
2001 Jul 1
Taurine modulates arginine vasopressin-mediated regulation of renal function.
2001 Jun
17 beta-estradiol protects neurons from ischemic damage and attenuates accumulation of extracellular excitatory amino acids.
2001 Jun
Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells.
2001 Jun 1
Reactive nitrogen oxygen species metabolize N-acetylbenzidine.
2001 Mar
Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters.
2001 Mar
Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation.
2001 Mar 16
Intrathecal magnesium sulfate attenuates algogenic behavior and spinal amino acids release after kainic acid receptor activation in rats.
2001 Mar 30
High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1.
2001 May
Cysteine regulates expression of cysteine dioxygenase and gamma-glutamylcysteine synthetase in cultured rat hepatocytes.
2001 May
Patents

Sample Use Guides

Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg.
Route of Administration: Oral
In Vitro Use Guide
Agonist properties of taurine on glycine receptor of supraoptic magnocellular neurones acutely dissociated from adult rats, using whole-cell voltage clamp. Responses to 1 mM taurine were blocked by strychnine but not by gabazine and showed no additivity with glycine-induced currents, indicating selective activation of glycine receptors.
Substance Class Chemical
Created
by admin
on Sat Dec 17 12:34:19 UTC 2022
Edited
by admin
on Sat Dec 17 12:34:19 UTC 2022
Record UNII
GQK0L6ZDHA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POTASSIUM TAURINE LAURATE
INCI  
INCI  
Official Name English
DODECANOIC ACID, 2-AMINOETHANESULFONIC, POTASSIUM SALT
Common Name English
L-TK
Brand Name English
POTASSIUM TAURINE LAURATE [INCI]
Common Name English
Code System Code Type Description
PUBCHEM
76963160
Created by admin on Sat Dec 17 12:34:19 UTC 2022 , Edited by admin on Sat Dec 17 12:34:19 UTC 2022
PRIMARY
FDA UNII
GQK0L6ZDHA
Created by admin on Sat Dec 17 12:34:19 UTC 2022 , Edited by admin on Sat Dec 17 12:34:19 UTC 2022
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY